Sugi Predict

Sugi Predict / Compounds / SCHEMBL1439256

SCHEMBL1439256

SCHEMBL1439256

CC(C)(C)OC(=O)N1CCCC(F)(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ USP30 Q70CQ3 3/20 0.45
▸ HPGD P15428 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ RORC P51449 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ SCD5 Q86SK9 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ PREP P48147 1/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028676 1.00 USP30 (0.45) USP30HPGDUSP2SMN1; SMN2MEN1
SCHEMBL2327550 0.91 USP30 (0.48) USP30HPGDUSP2SMN1; SMN2RORC
SCHEMBL14957517 0.91 USP30 (0.48) USP30HPGDUSP2SMN1; SMN2RORC
SCHEMBL14956683 0.91 USP30 (0.48) USP30HPGDUSP2SMN1; SMN2RORC
SCHEMBL27987902 0.89 USP30 (0.47) USP30HPGDUSP2SMN1; SMN2RORC
SCHEMBL27987896 0.89 USP30 (0.47) USP30HPGDUSP2SMN1; SMN2RORC
SCHEMBL31449900 0.88 HPGD (0.46) USP30HPGDUSP2SMN1; SMN2MEN1
SCHEMBL1441490 0.85 USP30 (0.46) USP30HPGDUSP2SMN1; SMN2MEN1
SCHEMBL12815812 0.85 USP30 (0.44) USP30HPGDUSP2SMN1; SMN2MEN1
SCHEMBL28779043 0.84 USP30 (0.46) USP30HPGDUSP2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025104443-A1 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-05-22 — — WO disclosed
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2024-07-25 — — US disclosed
CN-117751114-A Small molecule modulators of glucocerebrosidase activity and uses thereof 凡况生化公司 2024-03-22 — — CN disclosed
EP-4329880-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF Vanqua Bio, Inc. (US) 2024-03-06 — — EP disclosed
US-20230053411-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES BAYER AKTIENGESELLSCHAFT (DE) 2023-02-23 — — US disclosed
CN-110256418-B 1, 3-thiazol-2-yl substituted benzamides 拜耳公司 2023-01-20 — — CN disclosed
WO-2022232360-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF VANQUA BIO, INC. (US) 2022-11-03 — — WO disclosed
EP-3215150-B1 INHIBITORS OF MYOCARDIN-RELATED TRANSCRIPTION FACTOR AND SERUM RESPONSE FACTOR (MRTF/SRF)-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME UNIV MICHIGAN REGENTS (US) 2022-07-20 — — EP disclosed
US-11370784-B2 Cyano-substituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2022-06-28 — — US disclosed
US-11370784-B2 Cyano-substituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2022-06-28 — — US disclosed
US-20110130380-A1 Heteroaryl Kinase Inhibitors NOVARTIS AG (CH) 2011-06-02 — — US disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
WO-2011026917-A1 HETEROARYL COMPOUNDS AS KINASE INHIBITORS NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
WO-2011026904-A1 PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 — — US disclosed
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES SCHERING CORPORATION 2010-05-20 — — US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
US-7605155-B2 Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors SCHERING CORPORATION (US) 2009-10-20 — — US disclosed
US-20070082900-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-04-12 — — US disclosed
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230053411-A1 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES NAT1, HNMT, PMP22 USP30 4261/4885HPGD 670/4885USP2 3835/4885
US-20070082900-A1 Methods for inhibiting protein kinases PIM1, AURKC, PIM3 USP30 2723/4885HPGD 3890/4885USP2 2766/4885
US-11370784-B2 Cyano-substituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 USP30 1/4885HPGD 791/4885USP2 15/4885
US-20100125068-A1 METHODS FOR INHIBITING PROTEIN KINASES PIM1, AURKC, PIM3 USP30 2723/4885HPGD 3890/4885USP2 2766/4885
US-20110130380-A1 Heteroaryl Kinase Inhibitors CDK2, CDK1, CDKL1 USP30 1883/4885HPGD 1501/4885USP2 2623/4885
US-20240246952-A1 SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF GBA1, GAA, GBA2 USP30 2938/4885HPGD 1550/4885USP2 2620/4885
US-20070072881-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A USP30 2153/4885HPGD 1055/4885USP2 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.